Braidwell’s Beta Bionics BBNX Stock Holding History

Braidwell’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-140,000	Closed	-$1.71M	–	66
2025 Q1	$1.71M	Buy	+140,000	New	+$2.61M	0.06%	62

Other funds holding BBNX

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Braidwell's BBNX Position: Q2 2025 in Review

Braidwell sold out of Beta Bionics (BBNX) in Q2 2025, closing a stake of 140,000 shares — an estimated $1.71M sold.

Braidwell first reported a position in BBNX in Q1 2025 and held it in 1 quarter. The position peaked at $1.71M in Q1 2025. 116 funds tracked by Wall St. Rank hold BBNX as of Q2 2025.

Braidwell reported no remaining Beta Bionics position as of Q2 2025 after selling out during the quarter.
Braidwell sold 140,000 Beta Bionics shares in Q2 2025, an estimated $1.71M.
Braidwell first reported a position in Beta Bionics in Q1 2025 and held it in 1 quarter.
Braidwell's Beta Bionics position peaked at $1.71M in Q1 2025.
116 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.